These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 28178672)
1. Comparative analysis of microRNA expression profiles between A549, A549/DDP and their respective exosomes. Qin X; Yu S; Xu X; Shen B; Feng J Oncotarget; 2017 Jun; 8(26):42125-42135. PubMed ID: 28178672 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110 [TBL] [Abstract][Full Text] [Related]
3. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner. Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364 [TBL] [Abstract][Full Text] [Related]
4. MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Yuwen DL; Sheng BB; Liu J; Wenyu W; Shu YQ Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2650-2658. PubMed ID: 28678319 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1. Ma Y; Li X; Cheng S; Wei W; Li Y Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370 [TBL] [Abstract][Full Text] [Related]
6. Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor. Warnecke-Eberz U; Chon SH; Hölscher AH; Drebber U; Bollschweiler E Tumour Biol; 2015 Jun; 36(6):4643-53. PubMed ID: 25631748 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line. Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Exosomal miRNA in Blood as a Potential Diagnostic Biomarker for Human Non-Small Cell Lung Cancer. Xu Z; Wang Z; Sun H; Xin H Med Sci Monit; 2020 May; 26():e924721. PubMed ID: 32444593 [TBL] [Abstract][Full Text] [Related]
9. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. Zheng P; Chen L; Yuan X; Luo Q; Liu Y; Xie G; Ma Y; Shen L J Exp Clin Cancer Res; 2017 Apr; 36(1):53. PubMed ID: 28407783 [TBL] [Abstract][Full Text] [Related]
10. Exosomal MiR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer. Lin H; Zhang L; Zhang C; Liu P J Cell Mol Med; 2020 Aug; 24(16):8930-8941. PubMed ID: 32588541 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. Pei K; Zhu JJ; Wang CE; Xie QL; Guo JY Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4697-4704. PubMed ID: 27906433 [TBL] [Abstract][Full Text] [Related]
12. Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin. Xiao X; Yu S; Li S; Wu J; Ma R; Cao H; Zhu Y; Feng J PLoS One; 2014; 9(2):e89534. PubMed ID: 24586853 [TBL] [Abstract][Full Text] [Related]
13. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Zou J; Yin F; Wang Q; Zhang W; Li L Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572 [TBL] [Abstract][Full Text] [Related]
15. CLL Exosomes Modulate the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively Enriched in miR-202-3p. Farahani M; Rubbi C; Liu L; Slupsky JR; Kalakonda N PLoS One; 2015; 10(10):e0141429. PubMed ID: 26509439 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Ding G; Zhou L; Qian Y; Fu M; Chen J; Chen J; Xiang J; Wu Z; Jiang G; Cao L Oncotarget; 2015 Oct; 6(30):29877-88. PubMed ID: 26337469 [TBL] [Abstract][Full Text] [Related]
17. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression. Sui C; Meng F; Li Y; Jiang Y J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928 [TBL] [Abstract][Full Text] [Related]
18. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910 [TBL] [Abstract][Full Text] [Related]
19. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer. Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428 [TBL] [Abstract][Full Text] [Related]
20. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer. Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]